Biomaterials:深圳先进院等成功构筑新型黑磷药物控释系统

2018-07-13 佚名 深圳先进技术研究院

近日,中国科学院深圳先进技术研究院研究员喻学锋课题组与武汉大学口腔医学院教授张玉峰课题组合作,制备出一种负载黑磷及氯化锶的药物控释系统,有效修复大鼠股骨缺损。该项研究成果以Near-Infrared Light-Triggered Drug Delivery System Based on Black Phosphorus for in vivo Bone Regeneration 为题发表在生物

近日,中国科学院深圳先进技术研究院研究员喻学锋课题组与武汉大学口腔医学院教授张玉峰课题组合作,制备出一种负载黑磷及氯化锶的药物控释系统,有效修复大鼠股骨缺损。该项研究成果以Near-Infrared Light-Triggered Drug Delivery System Based on Black Phosphorus for in vivo Bone Regeneration 为题发表在生物材料期刊Biomaterials上。

由于肿瘤、创伤等导致的骨缺损问题一直是临床医生面临的一个巨大挑战,目前,国内外学者主要致力于寻找一种骨替代材料有效修复骨缺损。锶元素是一种能够有效促进骨修复的微量元素,研究表明,锶元素复合羟基磷灰石、生物玻璃等作为骨替代材料能够很好地修复骨缺损。然而,这种骨替代材料中有效锶离子释放浓度无法得到精确控制。近年来,利用各种外源性刺激如电场、磁场、超声等,控制药物释放被广泛研究。其中,近红外光因其具有较好的组织穿透能力,能够远程精准地控制药物释放。黑磷作为一种高效光热转换材料,因其良好的生物相容性及生物可降解性,近年来在生物医学领域备受关注。

在该研究中,该团队制备了一种负载了黑磷和氯化锶的聚乳酸(PLGA)微球,将其植入大鼠股骨缺损模型中,由于黑磷的光热转换功能,在近红外光照射下可造成局部升温至PLGA的玻璃化转变温度(55℃),导致PLGA微球破裂,从而实现锶离子的控释。通过调整照射的时间和位置即可控制锶离子在最佳时间和空间得以释放,发挥最佳药效,从而实现大鼠股骨骨缺损的有效修复(如图)。这种黑磷基载药系统不仅可用于骨组织再生,还有望拓展到各种需要精确药物控释的治疗体系中。


负载了黑磷和氯化锶的PLGA微球制备及修复大鼠股骨缺损示意图

该研究工作得到国家自然科学基金、广东省人才计划等的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918197, encodeId=c308191819e50, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 21 23:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811298, encodeId=a775181129875, content=<a href='/topic/show?id=09608e7593b' target=_blank style='color:#2F92EE;'>#药物控释#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87759, encryptionId=09608e7593b, topicName=药物控释)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Thu Jun 20 23:39:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050000, encodeId=01082050000ec, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Thu Jun 06 01:39:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331363, encodeId=51ec33136314, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jul 13 20:16:07 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331354, encodeId=6132331354d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 13 19:59:44 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2019-01-21 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918197, encodeId=c308191819e50, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 21 23:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811298, encodeId=a775181129875, content=<a href='/topic/show?id=09608e7593b' target=_blank style='color:#2F92EE;'>#药物控释#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87759, encryptionId=09608e7593b, topicName=药物控释)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Thu Jun 20 23:39:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050000, encodeId=01082050000ec, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Thu Jun 06 01:39:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331363, encodeId=51ec33136314, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jul 13 20:16:07 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331354, encodeId=6132331354d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 13 19:59:44 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918197, encodeId=c308191819e50, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 21 23:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811298, encodeId=a775181129875, content=<a href='/topic/show?id=09608e7593b' target=_blank style='color:#2F92EE;'>#药物控释#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87759, encryptionId=09608e7593b, topicName=药物控释)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Thu Jun 20 23:39:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050000, encodeId=01082050000ec, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Thu Jun 06 01:39:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331363, encodeId=51ec33136314, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jul 13 20:16:07 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331354, encodeId=6132331354d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 13 19:59:44 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918197, encodeId=c308191819e50, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 21 23:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811298, encodeId=a775181129875, content=<a href='/topic/show?id=09608e7593b' target=_blank style='color:#2F92EE;'>#药物控释#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87759, encryptionId=09608e7593b, topicName=药物控释)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Thu Jun 20 23:39:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050000, encodeId=01082050000ec, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Thu Jun 06 01:39:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331363, encodeId=51ec33136314, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jul 13 20:16:07 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331354, encodeId=6132331354d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 13 19:59:44 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1918197, encodeId=c308191819e50, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 21 23:39:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811298, encodeId=a775181129875, content=<a href='/topic/show?id=09608e7593b' target=_blank style='color:#2F92EE;'>#药物控释#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87759, encryptionId=09608e7593b, topicName=药物控释)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Thu Jun 20 23:39:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050000, encodeId=01082050000ec, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Thu Jun 06 01:39:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331363, encodeId=51ec33136314, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jul 13 20:16:07 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331354, encodeId=6132331354d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 13 19:59:44 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 医者仁心5538

    学习了

    0

相关资讯

Adv Mater:黑磷纳米药物运输体系,多模式联合治疗癌症

癌症已成为目前危害人类健康的主要疾病之一。癌症治疗所面临的挑战包括药物利用率低,效果差且易复发等问题。相比于传统的单一治疗方式,多模式联合治疗表现出巨大的优势。为实现多模式联合治疗,通常采用的方法是利用纳米药物载体对多种不同功能的药物进行负载,但大部分药物载体对药物的负载量低,严重限制了多模式治疗的应用。黑磷纳米片是继石墨烯之后新发现的一类新型二维纳米材料。与石墨烯相比,黑磷纳米片的多褶皱结构使其